Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Prostaglandin Analog [EPC]
Tafluprost is a potent prostaglandin analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension by increasing fluid drainage from the eye.
Name
Tafluprost
Raw Name
TAFLUPROST
Category
Prostaglandin Analog [EPC]
Drug Count
4
Variant Count
5
Last Verified
February 17, 2026
RxCUI
1244611, 1244616
UNII
1O6WQ6T7G3
About Tafluprost
Tafluprost is a potent prostaglandin analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension by increasing fluid drainage from the eye.
Detailed information about Tafluprost
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Tafluprost.
According to the FDA-approved labeling (2012), Tafluprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Open-angle glaucoma is a chronic condition where the drainage angle of the eye remains open, but the fluid (aqueous humor) does not drain properly, leading to increased pressure that can damage the optic nerve. If left untreated, this can result in permanent vision loss. Tafluprost works by enhancing the outflow of this fluid, thereby maintaining the pressure at a level that is less likely to cause nerve damage.
To understand how Tafluprost works, one must first understand the dynamics of fluid in the eye. The eye constantly produces a clear fluid called aqueous humor, which provides nutrients and maintains the eye's shape. To keep the pressure stable, an equal amount of fluid must drain out. In many forms of glaucoma, the drainage system becomes inefficient. Tafluprost acts as a Prostaglandin Receptor Agonist [MoA]. Specifically, it targets the FP receptors located in the ciliary muscle and the trabecular meshwork (the eye's drainage channels).
At the molecular level, Tafluprost is a prodrug (an inactive substance converted into an active drug within the body). Once applied to the eye, it is hydrolyzed (broken down by water/enzymes) by esterases in the cornea into its active form, tafluprost acid. This active acid binds with high affinity to the FP prostanoid receptors. This binding triggers a cascade of cellular events that increase the permeability of the tissues in the uveoscleral pathway. By opening up these 'alternative' drainage routes, Tafluprost allows the aqueous humor to flow out of the eye more freely, which effectively lowers the intraocular pressure.
Tafluprost is FDA-approved for the following indications:
While not officially FDA-approved for other uses, some healthcare providers may explore its use in other forms of glaucoma where prostaglandin analogs are known to be effective, though this is considered 'off-label' use.
Tafluprost is primarily available as a sterile, preservative-free ophthalmic solution. It is commonly packaged in single-use containers (vials) to ensure sterility without the need for preservatives like benzalkonium chloride (BAK), which can be irritating to the ocular surface. Each single-use container typically contains 0.3 mL of solution at a concentration of 0.0015%.
> Important: Only your healthcare provider can determine if Tafluprost is right for your specific condition. A comprehensive eye exam is necessary to diagnose glaucoma and determine the appropriate treatment strategy.
The standard adult dosage for Tafluprost (as per the Zioptan prescribing information) is one drop in the affected eye(s) once daily in the evening. It is critical not to exceed this frequency. Clinical studies have shown that dosing more than once daily may actually decrease the intraocular pressure-lowering effect of the medication. The evening administration is recommended because intraocular pressure typically fluctuates throughout a 24-hour cycle, and evening dosing has been shown to provide optimal pressure control during the early morning hours when pressure is often at its highest.
Tafluprost is currently NOT approved for use in pediatric patients. The safety and effectiveness of Tafluprost in children under the age of 18 have not been established. Because the eye is still developing in children, and because prostaglandin analogs can cause permanent changes in eye color and eyelash growth, healthcare providers generally exercise extreme caution and typically opt for other treatments unless specifically indicated.
Tafluprost has not been extensively studied in patients with significant renal (kidney) impairment. However, because the systemic exposure following topical ocular administration is extremely low, dosage adjustments are generally not required for patients with mild to moderate kidney disease. Patients with end-stage renal disease should be monitored closely by their physician.
Similar to renal impairment, there is limited data on Tafluprost use in patients with hepatic (liver) impairment. Given the minimal systemic absorption, no specific dosage adjustments are typically recommended, but healthcare providers should be informed of any history of liver disease.
No overall differences in safety or effectiveness have been observed between elderly and younger patients. Standard adult dosing is typically used for patients over the age of 65.
Proper administration is vital to ensure the medication works correctly and to minimize side effects. Follow these steps:
If you miss a dose of Tafluprost, apply it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not apply two drops to make up for a missed dose, as this can interfere with the drug's effectiveness and increase the risk of side effects.
An overdose of Tafluprost via the ocular route is unlikely to cause systemic toxicity due to the small volume of the eye drop. However, if the medication is accidentally swallowed, or if multiple drops are applied frequently, symptoms might include eye irritation, redness, or potentially systemic effects like low blood pressure or shortness of breath. In case of accidental ingestion, contact a Poison Control Center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop using the medication without medical guidance, as this could lead to a dangerous increase in eye pressure.
The most frequently reported side effect of Tafluprost is conjunctival hyperemia (redness of the white part of the eye). According to clinical trials, this occurs in approximately 4% to 20% of patients. This redness is caused by the dilation of blood vessels in the eye and is usually mild. It often diminishes over time as the eye adjusts to the medication. Other common effects include:
> Warning: Stop taking Tafluprost and call your doctor immediately if you experience any of these serious symptoms:
One of the most notable long-term effects of Tafluprost and other prostaglandin analogs is Prostaglandin-Associated Periorbitopathy (PAP). This involves a loss of fat around the eye socket, which can cause the eyes to appear 'sunken' (enophthalmos) and the upper eyelid crease to deepen. While this is primarily a cosmetic concern, it can affect how the eyelids function over many years.
Another long-term effect is the permanent change in iris color. If you have light-colored eyes (blue, green, or hazel), they may gradually turn brown. This change happens slowly and may not be noticeable for several months or years. Because the change is permanent, it is especially important to discuss this with your doctor if you are only treating one eye, as it could lead to a permanent difference in color between your two eyes (heterochromia).
No FDA black box warnings currently exist for Tafluprost. However, the FDA-approved labeling includes strong precautions regarding the potential for permanent pigmentary changes to the iris and the risks associated with ocular inflammation.
Report any unusual symptoms or persistent discomfort to your healthcare provider. Monitoring by an ophthalmologist is essential to ensure that side effects do not outweigh the benefits of intraocular pressure reduction.
Tafluprost is a potent ophthalmic medication that requires careful management. Patients must be aware that this drug can cause permanent physical changes to the eye. It is intended for topical ocular use only and should never be injected or swallowed. If you have a history of eye surgery, particularly cataract surgery, or if you have a history of eye inflammation, you must inform your healthcare provider, as Tafluprost may exacerbate these conditions.
There are currently no FDA black box warnings for Tafluprost. It is generally considered safe when used as directed under the supervision of an eye care professional.
Patients using Tafluprost should have regular follow-up appointments with their ophthalmologist or optometrist. These visits typically involve:
Immediately after instilling Tafluprost, your vision may be temporarily blurred. Do not drive, use machinery, or perform any activity that requires clear vision until you are certain your vision has returned to normal. This usually takes only a few minutes.
There are no known direct interactions between Tafluprost and alcohol. However, excessive alcohol consumption can sometimes affect intraocular pressure and general eye health. It is always best to discuss your alcohol intake with your doctor.
Do not stop using Tafluprost suddenly without consulting your doctor. Glaucoma is often a 'silent' disease with no symptoms until vision is lost. If you stop the medication, your intraocular pressure will likely return to its previous high levels, putting your vision at risk. There is no 'withdrawal syndrome' associated with Tafluprost, but the risk is the return of high eye pressure.
> Important: Discuss all your medical conditions, including any history of asthma or breathing problems, with your healthcare provider before starting Tafluprost.
There are no medications that are strictly contraindicated for use with Tafluprost. However, using two different prostaglandin analogs (e.g., using both Tafluprost and Latanoprost) simultaneously is generally avoided. Clinical studies suggest that using more than one prostaglandin analog can actually lead to a paradoxical increase in intraocular pressure or a significant reduction in the pressure-lowering effect. Always inform your doctor of all eye drops you are currently using.
While systemic interactions are rare due to low absorption, the following should be monitored:
There are no known interactions between Tafluprost and specific foods, including grapefruit, dairy, or high-fat meals. Because the drug is applied topically to the eye, its absorption is not affected by the digestive process.
There is limited data on interactions between Tafluprost and herbal supplements. However, supplements that are purported to affect eye pressure or blood flow (such as Ginkgo Biloba or Bilberry) should be discussed with your ophthalmologist. While they are unlikely to interact chemically with the eye drops, they may affect the underlying condition of glaucoma.
Tafluprost is not known to interfere with common laboratory blood or urine tests. Because the systemic concentration is so low, it does not typically reach levels that would cause false positives or negatives in diagnostic testing.
To minimize the risk of interactions and ensure maximum efficacy:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even if they are for conditions unrelated to your eyes.
Tafluprost is absolutely contraindicated in patients with a known hypersensitivity to tafluprost or any of the inactive ingredients in the formulation (such as glycerin, sodium dihydrogen phosphate dihydrate, or edetate disodium). An allergic reaction can manifest as severe itching, swelling of the eyelids, redness, or in rare cases, systemic anaphylaxis. If you have had an allergic reaction to other prostaglandin analogs (like latanoprost, travoprost, or bimatoprost), you must inform your doctor, as cross-sensitivity may occur.
Relative contraindications are conditions where the drug should be used only if the potential benefit outweighs the risk, and with close medical supervision:
Patients who have experienced significant side effects or allergic reactions to other drugs in the Prostaglandin Analog [EPC] class should be evaluated carefully. While the chemical structures differ slightly, the mechanism of action is the same, and similar ocular surface reactions may occur. If you experienced severe redness or swelling with Latanoprost (Xalatan) or Travoprost (Travatan Z), your doctor may choose to monitor your first few doses of Tafluprost very closely.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of eye infections or surgeries, before prescribing Tafluprost. Never use this medication if you are allergic to any of its components.
Tafluprost is classified under Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies of Tafluprost in pregnant women. Animal studies have shown that systemic administration of tafluprost can cause fetal harm and pregnancy loss at doses much higher than the human ocular dose. Because of the potential risk to the fetus, Tafluprost should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing age should discuss contraceptive options with their doctor while using this medication.
It is not known whether tafluprost or its metabolites are excreted in human milk. In animal studies, tafluprost has been found in the milk of lactating rats. Because many drugs are excreted in human milk, caution should be exercised when Tafluprost is administered to a nursing woman. To minimize the amount of drug that might reach the breast milk, women can practice punctal occlusion (pressing the corner of the eye) for several minutes after applying the drops.
Safety and effectiveness in pediatric patients have not been established. The use of Tafluprost is generally not recommended in children due to concerns about potential long-term changes in iris pigmentation and the lack of data regarding its effect on the developing eye.
Clinical data indicates that no overall differences in safety or effectiveness have been observed between elderly patients (65 years and older) and younger adult patients. The pharmacokinetic profile does not change significantly with age, and no dosage adjustment is necessary for the elderly. However, older patients may have more difficulty with the manual dexterity required to use single-use vials; caregivers should be trained to assist if necessary.
Tafluprost has not been specifically studied in patients with renal impairment. However, since the drug is rapidly metabolized and systemic levels are nearly undetectable (less than 10 pg/mL) after ocular use, renal impairment is not expected to affect the drug's safety or efficacy significantly. No dose adjustments are required for patients with GFR > 30 mL/min.
There is no specific data for patients with hepatic impairment. Given the low systemic exposure and the fact that the drug is primarily metabolized by beta-oxidation (similar to natural fatty acids) rather than solely by liver CYP enzymes, it is unlikely that liver disease would necessitate a dose change. Patients with severe cirrhosis should still be monitored for any unexpected systemic effects.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Tafluprost is a fluorinated, isopropyl ester analog of prostaglandin F2α. It is a highly selective agonist for the FP prostanoid receptor. The primary mechanism by which it reduces intraocular pressure is by increasing uveoscleral outflow. This is an alternative drainage pathway for aqueous humor that bypasses the traditional trabecular meshwork. By binding to FP receptors in the ciliary muscle, tafluprost induces changes in the extracellular matrix, reducing resistance to fluid flow. Some studies suggest it may also have a minor effect on increasing trabecular outflow, though the uveoscleral route is the primary target.
The reduction of intraocular pressure typically begins about 2 to 4 hours after the first administration, with the maximum effect reached after 12 hours. The effect is sustained for at least 24 hours, which allows for once-daily dosing. Tafluprost does not significantly affect heart rate or blood pressure, distinguishing it from ophthalmic beta-blockers.
| Parameter | Value |
|---|---|
| Bioavailability | High (Corneal absorption) |
| Protein Binding | >99% (Active acid) |
| Half-life | <30 minutes (Plasma) |
| Tmax | 10-15 minutes (Plasma) |
| Metabolism | Hydrolysis to active acid; then Beta-oxidation |
| Excretion | Renal and Biliary |
Tafluprost is a member of the Prostaglandin Analog [EPC] therapeutic class. Related medications include Latanoprost (Xalatan), Travoprost (Travatan Z), and Bimatoprost (Lumigan). Within this class, Tafluprost is distinguished by its fluorinated structure and its availability in preservative-free formulations, which may offer better tolerability for patients with ocular surface disease.
Medications containing this ingredient
Common questions about Tafluprost
Tafluprost is an ophthalmic (eye) solution used primarily to lower high pressure inside the eye in patients with open-angle glaucoma or ocular hypertension. By reducing this pressure, the medication helps prevent damage to the optic nerve, which is essential for maintaining clear vision. It belongs to a class of drugs called prostaglandin analogs, which work by increasing the natural drainage of fluid from the eye. It is often prescribed when other medications are not well-tolerated or are insufficient on their own. Regular use as directed by a healthcare provider is necessary to prevent permanent vision loss from glaucoma.
The most common side effect of Tafluprost is redness of the eyes, also known as conjunctival hyperemia, which affects up to 20% of users. Other frequent side effects include eye irritation, stinging, or a feeling like something is in the eye. Many patients also notice changes to their eyelashes, such as increased length, thickness, and darkness. Some people may experience temporary blurred vision immediately after putting the drops in. While most of these effects are mild, any persistent or severe discomfort should be reported to your eye doctor immediately.
There are no known direct interactions between alcohol and Tafluprost eye drops. Because the medication is applied locally to the eye and very little enters the bloodstream, alcohol consumption does not typically interfere with how the drug works. However, it is important to remember that overall health can impact eye pressure, and excessive alcohol use may have other health implications. You should always use Tafluprost exactly as prescribed, regardless of alcohol consumption. If you have concerns about how your lifestyle might affect your glaucoma treatment, discuss them with your healthcare provider.
Tafluprost is classified as Pregnancy Category C, meaning there is not enough research in humans to guarantee its safety during pregnancy. Animal studies have shown that very high doses can be harmful to a developing fetus, though the amount used in eye drops is much lower. Most doctors recommend using Tafluprost during pregnancy only if the benefit of saving the mother's vision outweighs the potential risks to the baby. If you are pregnant or planning to become pregnant, it is vital to discuss alternative treatments or safety measures with your ophthalmologist. They may suggest specific techniques to minimize the amount of medicine that enters your bloodstream.
After applying the first drop, Tafluprost begins to lower intraocular pressure within about 2 to 4 hours. The maximum pressure-lowering effect is usually reached approximately 12 hours after the dose is administered. Because the effect lasts for at least 24 hours, the medication only needs to be used once a day. It may take several weeks of consistent use for your doctor to determine the full extent of how well the medication is working for you. Regular follow-up appointments are necessary to monitor your eye pressure and ensure the treatment is effective.
You should never stop taking Tafluprost suddenly without first consulting your healthcare provider. Glaucoma is a chronic condition that usually has no symptoms; you cannot 'feel' your eye pressure rising. If you stop the medication, your eye pressure will likely return to dangerously high levels, which can cause permanent and irreversible damage to your optic nerve and lead to blindness. If you are experiencing side effects that make you want to stop the drug, talk to your doctor about alternative medications or different formulations. Consistency is the key to preserving your vision in glaucoma management.
If you miss a dose of Tafluprost, you should apply the missed drop as soon as you realize it. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply continue with your regular evening routine. Never apply two drops at once to make up for a missed one, as this can actually make the drug less effective and increase the risk of side effects like eye redness. To help you remember, try to link your eye drop routine to another nightly habit, such as brushing your teeth. If you frequently miss doses, discuss memory aids or other treatment options with your doctor.
There is no clinical evidence to suggest that Tafluprost causes weight gain. Because it is an eye drop with very minimal systemic absorption, it does not affect the metabolic processes or appetite-regulating hormones that typically lead to weight changes. If you experience unexpected weight gain while using Tafluprost, it is likely due to other factors such as diet, lifestyle, or other medications you may be taking. You should consult your primary care physician to investigate any significant changes in your weight or overall health. Tafluprost's side effects are almost exclusively limited to the eyes and the skin immediately surrounding them.
Tafluprost can generally be used alongside other medications, but you must inform your doctor about everything you are taking. If you use other eye drops, you should wait at least 5 to 10 minutes between applying Tafluprost and the other medication to ensure both are absorbed properly. There are very few systemic drug interactions, but using two different prostaglandin eye drops at the same time is usually avoided because it can interfere with pressure control. Always provide a full list of your prescriptions, over-the-counter drugs, and herbal supplements to your ophthalmologist to ensure your treatment plan is safe and effective.
As of 2024, generic versions of Tafluprost (the preservative-free 0.0015% solution) have become available in the United States and other markets. The brand-name version is known as Zioptan. Generic medications are required to have the same active ingredient, strength, and effectiveness as the brand-name version. Using a generic can often be more cost-effective for patients. However, availability may vary depending on your location and insurance plan. Talk to your pharmacist or healthcare provider to see if a generic version is appropriate for you and if it is covered by your prescription drug benefits.